Trials / Completed
CompletedNCT00674323
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
A Multicentre, Randomized, Double Masked, Exploratory, Indocyanine Green Angiography (ICGA) Guided Study of 6 Months Duration to Compare the Safety and Effect on Polyp Regression of Verteporfin Photodynamic Therapy (PDT) Alone or Added to Ranibizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with symptomatic macular polypoidal choroidal vasculopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Verteporfin Photodynamic Therapy | After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion. |
| DRUG | Ranibizumab | Ranibizumab at dose of 0.5 mg administered as an intravitreal injection. |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-05-01
- First posted
- 2008-05-07
- Last updated
- 2011-04-19
- Results posted
- 2011-01-25
Locations
5 sites across 5 countries: Hong Kong, Singapore, South Korea, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT00674323. Inclusion in this directory is not an endorsement.